Positive results for Phase III study of Eklira/Bretairis (Almirall) for COPD

Full results of ATTAIN, a six month pivotal study of the efficacy and safety of Eklira/Bretairis (inhaled aclidinium), from Almirall, in patients with moderate to severe Chronic Obstructive Pulmonary Disease have been published in the European Respiratory Journal. Significant improvement from baseline was observed with aclidinium 200 microg and 400 microg versus placebo for trough FEV1 (99 and 128 mL; both p<0.0001). improvements in trough fev1 with aclidinium 400 microg ranged from 105 to 140 ml throughout the study, which is consistently within the proposed meaningful clinically important difference (mcid) of over 100 ml. the drug also improved health status and relieved symptoms, and was well tolerated according to lead investigator professor paul jones, st george's, university of london. see:>"Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study." Paul W. Jones et al. Eur Respir J erj02255-2011; published ahead of print 2012, doi:10.1183/09031936.00225511